Transgenic mice expressing the neurotoxic C-terminus of .beta.-amyloid precursor protein

The present invention provides non-human, transgenic animals for use as a model for the study of Alzheimer's Disease. The animals exhibit pathology associated with Alzheimer's Disease. The phenotype is conferred in the animals by the introduction of an amyloid-containing polypeptide fragment of amyloid precursor protein, through the introduction of the DNA into the germ and somatic cells of the animal by transgenic methods.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

1. A transgenic mouse whose somatic and germ cells contain a transgene encoding an about 100 amino acid neurotoxic C-terminal fragment of the.beta.-amyloid precursor protein, wherein said transgene is operably linked to a brain tissue promoter, and wherein expression of said transgene results in the formation of punctate deposits in neuronal processes of the mouse's brain.

2. The mouse according to claim 1, wherein said transgene encodes APP-C104.

3. The mouse according to claim 1, wherein said transgene encodes the human polypeptide fragment APP-C104.

4. The mouse according to claim 1, wherein said promoter is the dystrophin neural promoter.

5. A progeny mouse of the mouse according to claim 1, wherein the somatic and germ cells of said progeny mouse contain a transgene encoding an about 100 amino acid neurotoxic C-terminal fragment of the 13-amyloid precursor protein, wherein said transgene is operably linked to a brain tissue promoter, and wherein the expression of said transgene results in the formation of punctuate deposits in neuronal processes of said progeny mouse's brain.

6. A method of determining the effect of compounds on the development of punctate deposits in neuronal processes of the mouse's brain, wherein said compounds are administered to the mouse of claims 1 or 2, and the effect of said compounds on the development of said deposits monitored.

7. The method according to claim 6, wherein the compounds are selected from the group consisting of hormones, polypeptides and nucleotides.

8. The method according to claim 6, wherein said monitoring comprises measuring the inhibitory effect of said compounds on the development of said deposit.

Referenced Cited
Foreign Patent Documents
0451700A1 October 1991 EPX
34794 August 1988 JPX
WO8906689 July 1989 WOX
WO9005138 May 1990 WOX
WO9014840 December 1990 WOX
WO9119810 December 1991 WOX
WO9206187 April 1992 WOX
Other references
  • Wirak, et al., Science, 253:323-325 (1991). Sandhut, et al., The Journal of Biological Chemistry, 266:21331-21334 (1991). Selkoe, Science, 354, 432-433 (1991). Marx, Science, 253, 266-267 (1991). Cork, et al., Animal Models of Degenerative Neurological Disease, in Animal Models: Assessing the Scope of Their Use in Biomedical Research, pp. 241-269 (1987) Alan R. Liss, Inc. Dyrks, et al., EMBO J. 7, 949 (1988). Kang, et al., Nature 325, 733 (1987). Goldgabar, et al., Science 235, 877 (1987). Tanzi, et al., Science 235, 880 (1987). Robakis, et al., Proc. Natl. Acad. Sci. USA 84, 4190 (1987). Ponte, et al., Nature 331, 525 (1988). Kitaguchi, et al., Nature 331, 530 (1988). Glenner, et al., Biochem. Biophys. Res. Commun. 120, 885 (1984). Glenner, et al., Biochem. Biophys. Res. Commun. 122, 1131 (1984). Masters, et al., Proc. Natl. Acad. Sci. USA 82, 4245 (1985). Esch, et al., Science 248, 1122 (1990). Yankner, et al., (1989) Science 245, 417. Wolf, et al., EMBO J. 9, 2079 (1990). Maruyama, et al., Nature 347, 566 (1990). Neve, et al., Neuron 5, 329 (1990). Boyce, F.M., et al., PNAS 88:1276 (1991).
Patent History
Patent number: 5672805
Type: Grant
Filed: Jul 18, 1991
Date of Patent: Sep 30, 1997
Assignee: The Regents of the University of California (Oakland, CA)
Inventor: Rachael L. Neve (Irvine, CA)
Primary Examiner: Deborah Crouch
Attorneys: Walter H. Dreger, Jan P. Brunelle
Application Number: 7/732,404
Classifications
Current U.S. Class: 800/2; 800/DIG1; 424/92; 935/62
International Classification: C12N 500; C12N 1500; A61K 4900;